Advertisement
BCYC vs VRCA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and VRCA is a Hold.
Aroon Indicator for BCYC shows an upward move is likely
BCYC's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 137 similar instances where the Aroon Indicator showed a similar pattern. In 121 of the 137 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 185 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
BCYC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCYC as a result. In 75 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for BCYC turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 42 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
BCYC moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.495) is normal, around the industry mean (3.498). P/E Ratio (-1.322) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (440.869).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
VRCA's RSI Indicator ascends from oversold territory
The RSI Oscillator for VRCA moved out of oversold territory on November 03, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 32 of the 34 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on VRCA as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for VRCA just turned positive on November 03, 2026. Looking at past instances where VRCA's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.
Following a +16.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in 221 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 46 cases where VRCA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
VRCA broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VRCA entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. VRCA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.724) is normal, around the industry mean (3.498). P/E Ratio (-1.833) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.496) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
BCYC | VRCA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 36 Fair valued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 100 | |
PRICE GROWTH RATING 1..100 | 73 | 63 | |
P/E GROWTH RATING 1..100 | 28 | 12 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCYC's Valuation (36) in the null industry is somewhat better than the same rating for VRCA (80) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew somewhat faster than VRCA’s over the last 12 months.
BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to VRCA’s over the last 12 months.
BCYC's SMR Rating (97) in the null industry is in the same range as VRCA (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to VRCA’s over the last 12 months.
VRCA's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as BCYC (73) in the null industry. This means that VRCA’s stock grew similarly to BCYC’s over the last 12 months.
VRCA's P/E Growth Rating (12) in the Pharmaceuticals Major industry is in the same range as BCYC (28) in the null industry. This means that VRCA’s stock grew similarly to BCYC’s over the last 12 months.
| BCYC | VRCA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 76% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 89% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 88% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 76% | 6 days ago 87% |
| Declines ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 83% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCYC’s FA Score shows that 1 FA rating(s) are green while VRCA’s FA Score has 1 green FA rating(s).
- BCYC’s FA Score: 1 green, 4 red.
- VRCA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCYC’s TA Score shows that 4 TA indicator(s) are bullish while VRCA’s TA Score has 4 bullish TA indicator(s).
- BCYC’s TA Score: 4 bullish, 4 bearish.
- VRCA’s TA Score: 4 bullish, 4 bearish.
Price Growth
BCYC (@Biotechnology) experienced а -6.65% price change this week, while VRCA (@Biotechnology) price change was +11.60% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
BCYC is expected to report earnings on Mar 02, 2027.
VRCA is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BCYC and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with PCVX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then PCVX could also see price increases.
| Ticker / NAME | Correlation To BCYC | 1D Price Change % | ||
|---|---|---|---|---|
| BCYC | 100% | -2.32% | ||
| PCVX - BCYC | 59% Loosely correlated | -2.04% | ||
| DYN - BCYC | 55% Loosely correlated | +0.88% | ||
| EDIT - BCYC | 54% Loosely correlated | +1.40% | ||
| RXRX - BCYC | 53% Loosely correlated | -4.35% | ||
| RCKT - BCYC | 52% Loosely correlated | -3.77% | ||
More | ||||
VRCA and
Correlation & Price change
A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with SVRA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To VRCA | 1D Price Change % | ||
|---|---|---|---|---|
| VRCA | 100% | -4.30% | ||
| SVRA - VRCA | 39% Loosely correlated | -1.69% | ||
| SANA - VRCA | 37% Loosely correlated | +0.50% | ||
| BCYC - VRCA | 36% Loosely correlated | -2.32% | ||
| KTTA - VRCA | 34% Loosely correlated | +0.40% | ||
| RYTM - VRCA | 34% Loosely correlated | +4.70% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BRKC | 43.39 | 0.32 | +0.75% |
| YieldMax BRK.B Option Income Strategy ETF (BRKC) | |||
| PAYH | 23.61 | 0.01 | +0.06% |
| TrueShares S&P Autocallable High Income ETF (PAYH) | |||
| CHGX | 33.05 | N/A | N/A |
| EA SERIES TRUST STANCE SUSTAINABLE BETA ETF | |||
| FELC | 42.62 | -0.13 | -0.30% |
| Fidelity Enhanced Large Cap Core ETF (FELC) | |||
| BHK | 8.30 | -0.04 | -0.48% |
| Blackrock Core BD TR | |||